Figure 2
From: Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma
Combined Allovectin and anti-CTLA-4 antibody immunotherapy: Comparing between Allovectin, dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium/dioleoyl phosphatidylethanolamine (DMRIE/DOPE) and VCL-1005 treatments. C57BL/6 mice were implanted subcutaneously on the flank with B16-F10 cells. At 6 days when tumors were palpable (average of 120 mm3), animals were randomized to treatment groups (day 1). Groups included: Allovectin (100 μg) plus 9H10 (hamster anti-murine-CTLA-4) or SHG-1 (hamster IgG control), VCL-1005 (100 μg) plus 9H10 or SHG-1, DMRIE/DOPE (43 μg, the same lipid mass present in 100 μg Allovectin) plus 9H10 or SHG-1, a no treatment control, and a 9H10 alone group. Allovectin, VCL-1005 and DMRIE/DOPE were delivered intratumorally as 50 μl volumes on days 1–4; 9H10 and SHG-1 were delivered intraperitoneally as previously described.49 Tumor volumes were determined using calipers every 3 days; animals were euthanized if moribund or when tumors exceeded 1000 mm3. Data for the control antibody groups only are shown. ○: no treatment control, Δ: DMRIE/DOPE-treated, ◊: VCL-1005-treated, ▪: Allovectin-treated.
